By Nancy Lapid
(Reuters) – The following is a summary of the latest scientific studies on the novel coronavirus and efforts to find a cure and vaccine for COVID-19, a viral illness.
The mRNA vaccine is likely to be effective for the Indian variety.
In laboratory experiments, both mRNA COVID-19 vaccines from Pfizer / Biotech and Modernna were effective against the rapidly spreading coronavirus across India and many other countries. Researchers revealed a variant called B.1.617.1 with blood serum samples from 15 volunteers with antibodies induced by Moderna vaccine, 10 subjects with antibodies after receiving Pfizer / BioNTech vaccine, and 24 subjects with antibodies. There was an antibody after recovering from COVID-19.In a paper published Monday on bioRxiv ahead of a peer review, the research team found that the Indian variant was 6.8 times more resistant to antibody neutralization in all three groups. “Despite this, most Sera from patients and all Sera from vaccinated subjects can still neutralize variable B.1.617.1,” they said. Go on, and it’s important to investigate how additional mutations affect the vaccine’s efficacy. (https://bit.ly/3uHwYbN)
People with HIV at risk of developing the more severe COVID-19 virus.
People with HIV infected with the coronavirus may be at a higher risk of serious illness, according to new data. Between August and October, researchers studied 955 HIV-infected people and 1,062 people without the infection.The COVID-19 rate was 3.7% among HIV-infected people, compared with 7.4% among those with HIV. HIV Among the 31 HIV-infected people and 70 who were not infected with the coronavirus, however, the chances of contracting the severe coronavirus were 5.52 times higher than those with HIV, the research team reported in The Lancet HIV. When recovered from COVID-19, antibody levels were significantly lower in people with HIV. This raises concerns that HIV infection can impair people’s immune responses to the virus and to vaccines. “People with HIV should be monitored after vaccination, where antibodies and T-cell activity are measured to ensure they have an adequate immune response to prevent immunosuppression.” Prevent cases of severe COVID-19 “(https://bit.ly/3y3kahI; https://bit.ly/3tEjFaC)
Rare heart damage with mild COVID-19.
A small UK study suggests that mild COVID-19 patients in healthy adults are unlikely to cause heart damage. Doctors compared 74 medical personnel who had been recovered from asymptomatic or asymptomatic COVID-19 with 75 without the coronavirus. Six months after the COVID-19 survivor was diagnosed, participants in both groups had no differences in heart structure or function. The findings, published Saturday in JACC: Cardiovascular Imaging, show that “If you are a healthy adult at work and suffer from untreated COVID-19, the effects of the heart six months later are rare at University College London and the Barts Heart Center in London,” said the study. It doesn’t prove that mild cases won’t cause heart damage. “But from the perspective of the population after the disease is mild, this is very reassuring” (https://bit.ly/3uEvb7l)
Open https://tmsnrt.rs/3c7R3Bl. In an external browser to view a Reuters graphic on developing vaccines.
(Reporting by Nancy Lapid, Linda Carroll and Megan Brooks; Edited by Bill Berkrot)